Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.52 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | PTPRA | P18433 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427048 | 0.86 | SMN1; SMN2 (0.52) | KDM4ESMN1; SMN2TDP1MAPTLIN28A | |
| SCHEMBL13211426 | 0.85 | KMT2A (0.51) | KDM4ESMN1; SMN2TDP1MAPTLIN28A | |
| SCHEMBL7976764 | 0.84 | SMN1; SMN2 (0.50) | KDM4ESMN1; SMN2TDP1MAPTLIN28A | |
| SCHEMBL427047 | 0.84 | SMN1; SMN2 (0.50) | KDM4ESMN1; SMN2TDP1MAPTLIN28A | |
| SCHEMBL7976763 | 0.84 | SMN1; SMN2 (0.50) | KDM4ESMN1; SMN2TDP1MAPTLIN28A | |
| SCHEMBL2755865 | 0.83 | KDM4E (0.62) | KDM4ETDP1ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL12313339 | 0.83 | NTRK1 (0.51) | KDM4ESMN1; SMN2TDP1MAPTLIN28A | |
| SCHEMBL28923770 | 0.81 | L3MBTL1 (0.60) | SMN1; SMN2TDP1MAPTLIN28AKCNA5 | |
| SCHEMBL24316287 | 0.81 | CYP1A2 (0.52) | KDM4ESMN1; SMN2TDP1MAPTLIN28A | |
| SCHEMBL676887 | 0.81 | SMN1; SMN2 (0.47) | KDM4ESMN1; SMN2TDP1MAPTLIN28A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699557-B1 | 3-(OXAZOL-2-YL-ETHOXY)- AND 3-(THIAZOL-2-YL-ETHOXY)-BENZAMIDE DERIVATIVES AS ANTI-BACTERIAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2017-08-16 | — | — | EP | claimed |
| EP-1399436-B1 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2005-03-16 | — | — | EP | disclosed |
| US-20040235753-A1 | Oxytocin agonists | PITT GRAY ROBERT WILLIAM (GB) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235753-A1 | Oxytocin agonists | OXTR, GNRHR, PRLHR | KDM4E 4329/4885SMN1; SMN2 840/4885TDP1 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.